TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 1151647

Group type: EXPERIMENTAL
Intervention: Corn oil‐in‐water emulsion (500 mg)
Number of subjects: 5

Group type: COMPARATOR
Intervention: Aqueous suspension (500 mg)
Number of subjects: 5

Group type: COMPARATOR
Intervention: Tablet A (500 mg)
Number of subjects: 5

Group type: COMPARATOR
Intervention: Tablet B (500 mg)
Number of subjects: 5
Study: 31289987

Group type: EXPERIMENTAL
Intervention: Computer-based intervention (12 hours)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Control group (usual educational curriculum)
Number of subjects: 32
Study: 28640061

Group type: EXPERIMENTAL
Intervention: Standing bouts every 30 min during 9-h sitting (STAND)
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: 30-min moderate-intensity walking bout followed by 8.5 h of sitting (MVPA)
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: 30-min moderate-intensity walking bout followed by 15-min standing bouts every 30 min during 8.5 h of sitting (MVPA + STAND)
Number of subjects: 14
Study: 25675335

Group type: EXPERIMENTAL
Intervention: Immediate FRT therapy
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Immediate VFE therapy
Number of subjects: 20

Group type: COMPARATOR
Intervention: Delayed FRT therapy
Number of subjects: 20

Group type: COMPARATOR
Intervention: Delayed VFE therapy
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: FRT therapy
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: VFE therapy
Number of subjects: 20
Study: 24776332

Group type: EXPERIMENTAL
Intervention: Simple strategy
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: Complex strategy
Number of subjects: 69

Group type: COMPARATOR
Intervention: Both strategies
Number of subjects: 69
Study: 21670776

Group type: EXPERIMENTAL
Intervention: Preoperative group: 2g amoxycillin capsules and 1g metronidazole tablets one hour before extraction
Number of subjects: 84

Group type: COMPARATOR
Intervention: Postoperative group: 500mg amoxycillin capsules thrice daily and 400mg metronidazole tablets thrice daily for five days
Number of subjects: 84
Study: 19308796

Group type: EXPERIMENTAL
Intervention: Needs-based computerized patient education
Number of subjects: 311

Group type: EXPERIMENTAL
Intervention: Conventional patient education
Number of subjects: 311

Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 311
Study: 16981032

Group type: EXPERIMENTAL
Intervention: Puncture in the left hypochondrium (Group LH)
Number of subjects: 62

Group type: COMPARATOR
Intervention: Puncture in the abdominal midline (Group ML)
Number of subjects: 62
Study: 14750201

Group type: EXPERIMENTAL
Intervention: Kan Jang (adjuvant treatment)
Number of subjects: 130

Group type: EXPERIMENTAL
Intervention: Immunal (adjuvant treatment)
Number of subjects: 130

Group type: COMPARATOR
Intervention: Standard treatment (Control group)
Number of subjects: 130
Study: 11384642

Group type: EXPERIMENTAL
Intervention: Micronized E(2) administered by the vaginal route
Number of subjects: 0

Group type: COMPARATOR
Intervention: Micronized E(2) administered by the oral route
Number of subjects: 0

Group type: COMPARATOR
Intervention: Controlled ovarian hyperstimulation (COH)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Exogenous E(2) by the vaginal route
Number of subjects: 0

Group type: COMPARATOR
Intervention: Endogenous E(2) produced by the ovaries
Number of subjects: 0
Study: 9246881

Group type: EXPERIMENTAL
Intervention: Alcoholic beverage
Number of subjects: 48

Group type: COMPARATOR
Intervention: Nonalcoholic beverage
Number of subjects: 48
Study: 8487324

Group type: EXPERIMENTAL
Intervention: rHuEPO (150 U/kg)
Number of subjects: 153
Study: 2961290

Group type: EXPERIMENTAL
Intervention: Fentanyl 1.5 micrograms/kg (F group; n = 142)
Number of subjects: 286

Group type: EXPERIMENTAL
Intervention: Low-dose nalbuphine 300 micrograms/kg (LN group; n = 103)
Number of subjects: 286

Group type: EXPERIMENTAL
Intervention: High-dose nalbuphine 500 micrograms/kg (HN group; n = 41)
Number of subjects: 286
Study: 29194177

Group type: EXPERIMENTAL
Intervention: Automated interactive micro‐prompting device
Number of subjects: 24

Group type: COMPARATOR
Intervention: Usual rehabilitation
Number of subjects: 24
Study: 27018610

Group type: EXPERIMENTAL
Intervention: Compassion Meditation (CM)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo oxytocin
Number of subjects: 0

Group type: COMPARATOR
Intervention: Familiarity intervention
Number of subjects: 0
Study: 25159356

Group type: EXPERIMENTAL
Intervention: SSM 30 µg
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: SSM 20 µg
Number of subjects: 100
Study: 23816571

Group type: EXPERIMENTAL
Intervention: Low-dose rhGH (25 μg/kg/day)
Number of subjects: 111

Group type: EXPERIMENTAL
Intervention: Intermediate-dose rhGH (50 μg/kg/day)
Number of subjects: 111

Group type: EXPERIMENTAL
Intervention: High-dose rhGH (100 μg/kg/day)
Number of subjects: 111

Group type: EXPERIMENTAL
Intervention: All doses of rhGH
Number of subjects: 111
Study: 20718901

Group type: EXPERIMENTAL
Intervention: Oral ivermectin (200 μg/kg, single dose)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Topical malathion lotion (0.5%, single application)
Number of subjects: 80
Study: 18559234

Group type: EXPERIMENTAL
Intervention: Mahuang Zhisou Capsule (MHZSC)
Number of subjects: 240

Group type: COMPARATOR
Intervention: Mahuang Zhisou Pill (Control)
Number of subjects: 240
Study: 17235418

Group type: EXPERIMENTAL
Intervention: Various drugs including 5‐Methyltetrahydrofolate, 9‐aminocamptothecin, and others
Number of subjects: 0
Study: 12825306

Group type: EXPERIMENTAL
Intervention: 27-gauge Whitacre-point needle (group I)
Number of subjects: 1555

Group type: COMPARATOR
Intervention: 27-gauge Quincke-point needle (group II)
Number of subjects: 1555
Study: 10980228

Group type: EXPERIMENTAL
Intervention: P-wave signal-averaged electrocardiogram (SAECG)
Number of subjects: 93
Study: 9012325

Group type: EXPERIMENTAL
Intervention: Nitrate exposure (55.70-87.98 mg/l)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Control group (nitrate concentration 0.7 mg/l)
Number of subjects: 70
Study: 1473544

Group type: EXPERIMENTAL
Intervention: Technique A (60 cycles/min, IT 0.33s, I:E 1:2)
Number of subjects: 181

Group type: COMPARATOR
Intervention: Technique B (30 cycles/min, IT 1.0s, I:E 1:1 to 2:1)
Number of subjects: 181

Group type: EXPERIMENTAL
Intervention: Technique A (60 cycles/min, IT 0.33s) in subgroup 31-32 weeks gestation
Number of subjects: 181

Group type: EXPERIMENTAL
Intervention: Technique A (60 cycles/min, IT 0.33s) in most immature group (< 28 weeks)
Number of subjects: 181
Study: 3155742

Group type: EXPERIMENTAL
Intervention: Seven milliliters of methylprednisolone acetate and procaine
Number of subjects: 73

Group type: EXPERIMENTAL
Intervention: Eighty milligrams of methylprednisolone acetate combined with five milliliters of 1 percent procaine
Number of subjects: 73

Group type: COMPARATOR
Intervention: Two milliliters of sterile saline combined with five milliliters of 1 percent procaine
Number of subjects: 73
Study: 30057033

Group type: EXPERIMENTAL
Intervention: Aromatherapy with 0.5% Citrus aurantium blossom essential oil
Number of subjects: 62

Group type: COMPARATOR
Intervention: Control group with inhalation of odorless sweet almond oil
Number of subjects: 62
Study: 26918853

Group type: EXPERIMENTAL
Intervention: Bilastine 10 mg
Number of subjects: 509

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 509
Study: 23147277

Group type: EXPERIMENTAL
Intervention: Intensive Care (IC)
Number of subjects: 1461

Group type: COMPARATOR
Intervention: Usual Care (UC)
Number of subjects: 1461
Study: 22393922

Group type: EXPERIMENTAL
Intervention: New ultrasonic dissector (NUD)
Number of subjects: 261

Group type: COMPARATOR
Intervention: Conventional hemostasis (CH)
Number of subjects: 261
Study: 20045311

Group type: EXPERIMENTAL
Intervention: Second-line treatment for advanced NSCLC
Number of subjects: 1239

Group type: EXPERIMENTAL
Intervention: Best prognostic score category (<5)
Number of subjects: 1239

Group type: EXPERIMENTAL
Intervention: Intermediate prognostic score category (5-9)
Number of subjects: 1239

Group type: EXPERIMENTAL
Intervention: Worst prognostic score category (>9)
Number of subjects: 1239
Study: 18532899

Group type: EXPERIMENTAL
Intervention: Naturopathic medicine plus usual care
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: MS education plus usual care
Number of subjects: 45

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 45
Study: 15691817

Group type: EXPERIMENTAL
Intervention: Structured Problem‐Related Anatomy Demonstrations
Number of subjects: 176
Study: 12610743

Group type: EXPERIMENTAL
Intervention: Rosuvastatin 10 mg for 14 days
Number of subjects: 18
Study: 10536354

Group type: EXPERIMENTAL
Intervention: Fine-needle aspiration (FNA) procedure
Number of subjects: 1196
Study: 8934377

Group type: EXPERIMENTAL
Intervention: Perindopril (4 mg daily) plus indapamide (2.5 mg daily)
Number of subjects: 6000

Group type: COMPARATOR
Intervention: Matching placebo for patients without an indication for or contraindication to treatment with a diuretic
Number of subjects: 6000

Group type: EXPERIMENTAL
Intervention: Perindopril alone
Number of subjects: 6000

Group type: COMPARATOR
Intervention: Matching placebo for all other patients
Number of subjects: 6000

Group type: EXPERIMENTAL
Intervention: Not specified
Number of subjects: 6000
Study: 1931394

Group type: EXPERIMENTAL
Intervention: Sevoflurane anaesthesia
Number of subjects: 30

Group type: COMPARATOR
Intervention: Halothane anaesthesia
Number of subjects: 30
Study: 7450409

Group type: EXPERIMENTAL
Intervention: Nifedipine (10-20 mg sublingually before each meal)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 31973041

Group type: EXPERIMENTAL
Intervention: Weekly text messages with a single item stress question
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: High-stress subgroup
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: High exhaustion scores
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Objective workload
Number of subjects: 0
Study: 30367450

Group type: EXPERIMENTAL
Intervention: Strategy-focused instruction (experimental condition)
Number of subjects: 101

Group type: COMPARATOR
Intervention: Practice-matched control condition
Number of subjects: 101
Study: 28964994

Group type: EXPERIMENTAL
Intervention: Standard weekly therapist support
Number of subjects: 180

Group type: COMPARATOR
Intervention: Optional weekly therapist support
Number of subjects: 180
Study: 25585272

Group type: EXPERIMENTAL
Intervention: Acceptance and Commitment Therapy (ACT)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Applied Relaxation (AR)
Number of subjects: 60
Study: 24968576

Group type: EXPERIMENTAL
Intervention: Exercise Group (EG)
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Massage and Exercise Group (MEG)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Control Group (CG)
Number of subjects: 25
Study: 21426323

Group type: EXPERIMENTAL
Intervention: Gamma Knife radiosurgery (RS) at 20 Gy or 24 Gy, 5.5‐7.5 ml at the 50% isodose volume
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Gamma Knife radiosurgery (RS)
Number of subjects: 30
Study: 19472126

Group type: EXPERIMENTAL
Intervention: Atropine sulfate
Number of subjects: 64

Group type: COMPARATOR
Intervention: Hypertonic saline solution (placebo)
Number of subjects: 64
Study: 17410044

Group type: EXPERIMENTAL
Intervention: Immediate treatment with 40,000 U of epoetin alfa once weekly at chemotherapy initiation
Number of subjects: 216

Group type: COMPARATOR
Intervention: Delayed treatment with epoetin alfa (no treatment unless Hb decreased to < 10 g/dl)
Number of subjects: 216

Group type: EXPERIMENTAL
Intervention: Both immediate and delayed groups
Number of subjects: 216
Study: 15492149

Group type: EXPERIMENTAL
Intervention: Laparoscopic gastric bypass
Number of subjects: 645

Group type: EXPERIMENTAL
Intervention: Laparoscopic vertical banded gastroplasty
Number of subjects: 645

Group type: EXPERIMENTAL
Intervention: Both surgical interventions
Number of subjects: 645
Study: 14679785

Group type: EXPERIMENTAL
Intervention: Test group (mixed green vegetable and fruit beverage containing broccoli and cabbage)
Number of subjects: 77

Group type: COMPARATOR
Intervention: Control group (placebo sample made from the same materials but without broccoli and cabbage)
Number of subjects: 77

Group type: EXPERIMENTAL
Intervention: Test group
Number of subjects: 77
Study: 10203367

Group type: EXPERIMENTAL
Intervention: CML (carboxymethyllysine)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Pentosidine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: MDA-lysine (malondialdehyde-lysine)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 4-hydroxynonenal-protein adduct
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Acrolein-protein adduct
Number of subjects: 0

Group type: COMPARATOR
Intervention: MDA-lysine
Number of subjects: 0

Group type: COMPARATOR
Intervention: CML, Pentosidine, Acrolein-protein adduct
Number of subjects: 0
Study: 7760256

Group type: EXPERIMENTAL
Intervention: d-amphetamine (0.2 mg/kg)
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: d-amphetamine (0.4 mg/kg)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22
Study: 2148830

Group type: EXPERIMENTAL
Intervention: Epirubicin plus Medroxyprogesterone acetate (MPA)
Number of subjects: 79

Group type: COMPARATOR
Intervention: Epirubicin plus placebo
Number of subjects: 79

Group type: EXPERIMENTAL
Intervention: Estramustine phosphate
Number of subjects: 79
Study: 7002179

Group type: EXPERIMENTAL
Intervention: Bupivacaine 0.75%
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Etidocaine 1.5%
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Prilocaine 3%
Number of subjects: 0
Study: 31116967

Group type: EXPERIMENTAL
Intervention: Molecular typing and antibiotic susceptibility testing of K. pneumoniae isolates
Number of subjects: 100
Study: 28927680

Group type: EXPERIMENTAL
Intervention: Digital Action Plan (DAP)
Number of subjects: 510

Group type: COMPARATOR
Intervention: Written Action Plan (WAP)
Number of subjects: 510
Study: 25670039

Group type: EXPERIMENTAL
Intervention: Laryngeal Mask Airway (LMA)
Number of subjects: 64

Group type: COMPARATOR
Intervention: Endotracheal Intubation (ETI)
Number of subjects: 64
Study: 24021935

Group type: EXPERIMENTAL
Intervention: Continuous femoral nerve blockade
Number of subjects: 60

Group type: COMPARATOR
Intervention: Conventional patient-controlled analgesia
Number of subjects: 60
Study: 21118604

Group type: EXPERIMENTAL
Intervention: Creatine supplementation (20 g for 5 days)
Number of subjects: 128

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 128
Study: 19234482

Group type: EXPERIMENTAL
Intervention: Tissue-cultured mountain ginseng extract (TMGE) 1000 mg twice a day
Number of subjects: 143

Group type: COMPARATOR
Intervention: Placebo 1000 mg twice a day
Number of subjects: 143
Study: 17556685

Group type: EXPERIMENTAL
Intervention: Low-fat snack (30.8% of energy from fat, 5.2% of energy from PUFAs)
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: High-PUFA snack (36.3% of energy from fat, 9.7% of energy from PUFAs)
Number of subjects: 33

Group type: COMPARATOR
Intervention: High-fat snack (37.9% of energy from fat, 5.8% of energy from PUFAs)
Number of subjects: 33
Study: 15235386

Group type: COMPARATOR
Intervention: Bevacizumab alone
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Bevacizumab plus thalidomide
Number of subjects: 22
Study: 11585273

Group type: EXPERIMENTAL
Intervention: Psychosocial support for early breast cancer patients
Number of subjects: 84

Group type: COMPARATOR
Intervention: Psychosocial support for advanced breast cancer patients
Number of subjects: 84
Study: 9647684

Group type: EXPERIMENTAL
Intervention: Rote serial-order memory task
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Elaborative category memory task
Number of subjects: 10

Group type: COMPARATOR
Intervention: High recallers
Number of subjects: 10

Group type: COMPARATOR
Intervention: Low recallers
Number of subjects: 10
Study: 7926494

Group type: EXPERIMENTAL
Intervention: Omeprazole 20 mg once daily
Number of subjects: 392

Group type: EXPERIMENTAL
Intervention: Omeprazole 10 mg once daily
Number of subjects: 392

Group type: COMPARATOR
Intervention: Ranitidine 150 mg twice daily
Number of subjects: 392
Study: 31024091

Group type: EXPERIMENTAL
Intervention: Maternal n-3 PUFA levels
Number of subjects: 238

Group type: EXPERIMENTAL
Intervention: Maternal DHA levels
Number of subjects: 238

Group type: EXPERIMENTAL
Intervention: Twin births
Number of subjects: 238

Group type: EXPERIMENTAL
Intervention: Birth weight in kilograms
Number of subjects: 238

Group type: EXPERIMENTAL
Intervention: Maternal n-6 PUFA levels
Number of subjects: 238

Group type: EXPERIMENTAL
Intervention: Maternal MUFA levels
Number of subjects: 238

Group type: EXPERIMENTAL
Intervention: Maternal MUAC
Number of subjects: 238

Group type: EXPERIMENTAL
Intervention: Male sex
Number of subjects: 238

Group type: EXPERIMENTAL
Intervention: Maternal plasma AA levels
Number of subjects: 238
Study: 31578141

Group type: EXPERIMENTAL
Intervention: VENUSS prognostic model
Number of subjects: 556
Study: 27641918

Group type: EXPERIMENTAL
Intervention: Radiofrequency neurolysis
Number of subjects: 28

Group type: COMPARATOR
Intervention: Local anesthetic and corticosteroid block
Number of subjects: 28
Study: 26279196

Group type: EXPERIMENTAL
Intervention: Whole-body vibration training (WBVT) with 4 × 2 minutes of bilateral dynamic squat exercises on a side‐alternating vibration platform at 24 to 26 Hz
Number of subjects: 83

Group type: COMPARATOR
Intervention: Control group (CON) with the same amount of exercise time on the floor
Number of subjects: 83

Group type: EXPERIMENTAL
Intervention: Whole-body vibration training (WBVT)
Number of subjects: 83

Group type: COMPARATOR
Intervention: Control group (CON)
Number of subjects: 83
Study: 22902255

Group type: EXPERIMENTAL
Intervention: High-intensity resistance exercise with whole-body vibration (WBV+RE)
Number of subjects: 10

Group type: COMPARATOR
Intervention: High-intensity resistance exercise (RE)
Number of subjects: 10
Study: 20652398

Group type: EXPERIMENTAL
Intervention: Sunitinib (arm A)
Number of subjects: 55

Group type: COMPARATOR
Intervention: No therapy (arm B)
Number of subjects: 55
Study: 18204125

Group type: EXPERIMENTAL
Intervention: Controlled inhalation of tobramycin (150 mg, twice daily for three days)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Conventional inhalation of tobramycin (300 mg, twice daily for three days)
Number of subjects: 16
Study: 15572485

Group type: EXPERIMENTAL
Intervention: Laparoscopic Burch colposuspension
Number of subjects: 72

Group type: COMPARATOR
Intervention: Tension-free vaginal tape (TVT)
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 72
Study: 11822351

Group type: EXPERIMENTAL
Intervention: Fluoxetine
Number of subjects: 65

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 65
Study: 10212857

Group type: EXPERIMENTAL
Intervention: Budesonide inhaler exhaled through the nose
Number of subjects: 49

Group type: COMPARATOR
Intervention: Combination of budesonide metered dose inhaler with budesonide nasal spray
Number of subjects: 49
Study: 8847426

Group type: EXPERIMENTAL
Intervention: 41/min oxygen in 35 patients
Number of subjects: 78

Group type: COMPARATOR
Intervention: No supplemental oxygen therapy
Number of subjects: 78
Study: 2215824

Group type: EXPERIMENTAL
Intervention: Plax
Number of subjects: 10

Group type: COMPARATOR
Intervention: Water
Number of subjects: 10
Study: 111293

Group type: EXPERIMENTAL
Intervention: Alcoholic beverage
Number of subjects: 64

Group type: COMPARATOR
Intervention: Nonalcoholic beverage
Number of subjects: 64
Study: 30925360

Group type: EXPERIMENTAL
Intervention: 2% linseed oil (LO)
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Increasing dietary LO (1%, 2%, 4%)
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: 4% linseed oil (LO)
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: 1% and 2% linseed oil (LO)
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: 2% and 4% linseed oil (LO)
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Adding linseed oil (LO) in diets
Number of subjects: 96
Study: 28751002

Group type: EXPERIMENTAL
Intervention: Intracorporeal purse string suture ligation of the hernia sac at internal inguinal ring (IIR) leaving the sac intact
Number of subjects: 132

Group type: COMPARATOR
Intervention: Disconnection of the hernia sac with intracorporeal suturing of proximal part at IIR
Number of subjects: 132
Study: 25835747

Group type: EXPERIMENTAL
Intervention: Negative Flexible Sigmoidoscopy (FSG)
Number of subjects: 21925
Study: 23524696

Group type: EXPERIMENTAL
Intervention: Pregabalin 75 mg
Number of subjects: 143

Group type: EXPERIMENTAL
Intervention: Pregabalin 150 mg
Number of subjects: 143

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 143
Study: 21372609

Group type: EXPERIMENTAL
Intervention: Intervention (I) - School-based intervention including six nutrition units and 20-min running games in the first year.
Number of subjects: 1192

Group type: COMPARATOR
Intervention: Non-Intervention (NI) - Control group with no intervention.
Number of subjects: 1192

Group type: EXPERIMENTAL
Intervention: Intervention (I) in high socio-economic status (SES) students.
Number of subjects: 1192

Group type: COMPARATOR
Intervention: Non-Intervention (NI) in high socio-economic status (SES) students.
Number of subjects: 1192
Study: 20040088

Group type: EXPERIMENTAL
Intervention: Individualized Action Plan (AP) intervention
Number of subjects: 245

Group type: COMPARATOR
Intervention: Usual care (Control)
Number of subjects: 245
Study: 17192768

Group type: EXPERIMENTAL
Intervention: Depo-medroxyprogesterone acetate (DMPA)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Nelfinavir
Number of subjects: 70

Group type: COMPARATOR
Intervention: Efavirenz
Number of subjects: 70

Group type: COMPARATOR
Intervention: Nevirapine
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: DMPA
Number of subjects: 70
Study: 15174909

Group type: EXPERIMENTAL
Intervention: Carotid Endarterectomy (CEA)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Carotid Artery Stenting (CAS)
Number of subjects: 25
Study: 11755836

Group type: EXPERIMENTAL
Intervention: Grading by trained technicians of horizontal cup/disk ratio from optic disk stereophotographs
Number of subjects: 1636

Group type: EXPERIMENTAL
Intervention: Estimates of horizontal cup/disk ratio from sequential full-frame photographs
Number of subjects: 1636

Group type: EXPERIMENTAL
Intervention: Gradings by technicians
Number of subjects: 1636
Study: 9840600

Group type: EXPERIMENTAL
Intervention: Mebendazole (anthelmintic)
Number of subjects: 336

Group type: EXPERIMENTAL
Intervention: Health education
Number of subjects: 336

Group type: EXPERIMENTAL
Intervention: Mebendazole and health education
Number of subjects: 336

Group type: COMPARATOR
Intervention: Placebo (control)
Number of subjects: 336

Group type: COMPARATOR
Intervention: Egg-negative children (control)
Number of subjects: 336